ATXN1 and Huntington disease: Since (CUG)7 targets expanded CAG repeats it potentially may offer a more widespread therapy for other polyglutamine disorders besides HD, such as several spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA17), dentatorubral-pallidoluysian atrophy (DRPLA) and spinal-bulbar muscular atrophy (SBMA).